Navigation Links
Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
Date:7/17/2008

phy and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com.

About Third Wave, Inc.

Third Wave develops and markets molecular diagnostic reagents for a variety of DNA and RNA analysis applications to meet the needs of its customers. Third Wave offers a number of products based on its Invader(R) chemistry for clinical testing. Third Wave offers in vitro diagnostic kits, and analyte specific, general purpose, and research use only reagents for nucleic acid analysis. For more information about Third Wave and its products, please visit Third Wave's website at http://www.twt.com.

Additional Information

The description contained herein is neither an offer to purchase nor a solicitation of an offer to sell shares of Third Wave. The tender offer is being made pursuant to a Tender Offer Statement and related materials. Third Wave shareholders are advised to read the Tender Offer Statement and related materials filed by Hologic with the U.S. Securities and Exchange Commission (the "SEC"). At the time the tender offer commenced, Hologic and the Purchaser (a direct wholly owned subsidiary of Hologic) filed a Tender Offer Statement on Schedule TO containing an Offer to Purchase, the form of the letter of transmittal and other documents relating to the tender offer, and Third Wave filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer, including the terms and conditions of the tender offer, and stockholders of Third Wave are urged to read them carefully. Stockholders of Third Wave are able to obtain a free copy of these documents at '/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
2. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
3. FDA Accepts Immucors Response to Warning Letter
4. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
5. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
6. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
7. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
8. FDA Accepts Ranexa(R) sNDA and NDA for Filing
9. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
10. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
11. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Last week, Representatives Gus Bilirakis (R-FL) ... bold bipartisan step on behalf of patients with ... co-sponsors of the legislation include Representatives McCaul (R-TX) ... makers and innovators to "repurpose" major market drugs ... opens the door to the development of hundreds ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... S.A., a,French drug and diagnostic discovery company, today announces ... 2007., 2007 Key Events, - Milestone reached ... AGN ) in view of the initiation of Phase ... - Approval by the AFSSAPS (Agence Francaise de ...
... Germany, March 5 In mid-March the German,Bundestag (Lower ... the German Stem,Cell Act. The opposing poles in the ... apart: its proponents are calling for the complete,liberalisation of ... of a,general ban on the use of human stem ...
... Statins Alone, in Decreasing Cardiovascular Events in Diabetics with Haptoglobin ... ... March 5 Synvista,Therapeutics, Inc. (Amex: SYI ) announces the publication ... E to statin therapy prevented more cardiovascular events (heart,attack, stroke and cardiovascular ...
Cached Biology Technology:ExonHit Therapeutics - 2007 Financial Results 2ExonHit Therapeutics - 2007 Financial Results 3ExonHit Therapeutics - 2007 Financial Results 4ExonHit Therapeutics - 2007 Financial Results 5ExonHit Therapeutics - 2007 Financial Results 6ExonHit Therapeutics - 2007 Financial Results 7ExonHit Therapeutics - 2007 Financial Results 8ExonHit Therapeutics - 2007 Financial Results 9ExonHit Therapeutics - 2007 Financial Results 10ExonHit Therapeutics - 2007 Financial Results 11ExonHit Therapeutics - 2007 Financial Results 12A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 2Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 3Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes 4
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... (November 4, 2014) — Think about the way our ... do neighboring cells know that they are supposed to ... do these tissues find the correct place and alignment? ... these crucial questions. , In a new study, UM ... communicate with their surrounding neighbors, at the head-trunk region. ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... diabetes during pregnancy is directly controlled by serotonin, a ... a neurotransmitter, and is influenced by the amount of ... to new findings of an international team led by ... to simple dietary solutions and possible therapeutics for the ...
... rich? Smithsonian researchers have new evidence that the answer ... to a study published in the journal, Nature ., ... not grow and survive well under their mothers or other ... fellow at the University of WisconsinMilwaukee and the Smithsonian Tropical ...
... available in Spanish . , At a time ... Service (ARS)-funded scientists have contributed to a limited but growing ... cognitive function. Cognitive function is measured by the ... use available information for activities of daily life. Alzheimer,s disease, ...
Cached Biology News:Gestational diabetes linked to serotonin and dietary protein 2Gestational diabetes linked to serotonin and dietary protein 3Biodiversity's holy grail is in the soil 2Vitamin D and mental agility in elders 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Viruses microRNA Microarray ...
Biology Products: